Effects of Sustained-release Oral Sodium Nitrite Supplementation on Pain-related Outcomes and Peri- and Postoperative Physiology in People Undergoing Unilateral All-component Revision Total Knee Arthroplasty

This study will determine whether a drug called sodium nitrite helps improve pain and post-operative recovery associated with knee replacement surgery.

Start Date01 Jun 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT05798481

/ RecruitingEarly Phase 1IIT

A Pilot Pre-Phase 1 Clinical Trial to Study How Administering Sublingual Nitric Oxide Donor S-nitroso-N-acetylcysteine Affects the Systemic Blood Pressure in Healthy Human Volunteers.

The purpose of the study is to increase the in vivo levels of nitric oxide by generating nitric oxide donor compound S-nitrosoacetylcysteine (SNOAC) using the mixture of sodium nitrite and N-acetylcysteine crystals in the sublingual space. The generated SNOAC rapidly diffuses into blood circulation thereby decrease the systemic blood pressure. This compound can be an alternative to organic nitrate NO donor drugs without developing tolerance in patients.

Start Date01 Mar 2024

Sponsor / Collaborator

The University of Alabama at Birmingham

ACTRN12622001330730

/ RecruitingPhase 1/2IIT

Elucidating the effects of nebulized sodium nitrite and argon on blood pressure and cerebrovascular haemodynamics in healthy adults and hypertensive patients

Start Date09 Jan 2023

Sponsor / Collaborator

Auckland University

100 Clinical Results associated with Sodium nitrite

100 Translational Medicine associated with Sodium nitrite

100 Patents (Medical) associated with Sodium nitrite

19,166

Literatures (Medical) associated with Sodium nitrite

01 Aug 2025·FOOD CHEMISTRY

Biotransformation-induced chemical modifications and nitrite production in beetroot and arugula extracts: Toward natural alternatives to synthetic preservatives in the meat industry

Article

Author: Ribeiro, Halley Dayane Dos Santos ; Araújo, Íris Braz da Silva ; Batista, Diego Silva ; Henschel, Juliane Maciel ; Ribeiro, José Evangelista Santos ; Dantas, Aline Macedo ; Silva, Elen Carla Alves da ; Santos, Maria de Fátima Clementino Dos ; Silva, Fábio Anderson Pereira da ; Ramalho, Isabelly da Silva ; Silva Filho, José Narciso Francisco da ; Ferreira, Valquíria Cardoso da Silva

The search for natural food additives is a growing priority for the modern food industry, especially in efforts to replace synthetic curing salts, which are linked to adverse health effects in processed meat products. One promising approach involves the use of pre-converted nitrate-rich plant extracts as an alternative to commercial sodium nitrite. However, the impact of the biotransformation process on the chemical and antioxidant properties of these extracts remains poorly understood. This study investigated the effects of biotransformation duration on the chemical composition and antioxidant capacity of beetroot and arugula extracts using commercial starter culture (Lyocarni SBM-11). Three extract formulations were prepared: R100 (100 % arugula), R50B50 (50 % arugula +50 % beetroot) and B100 (100 % beetroot). Throughout the incubation period, the beetroot extract exhibited the highest levels of total phenolics (139.4 to 99.1 mg GAE.100 mL^-1) and antioxidant activity, as assessed by DPPH (8.7 to 4.2 mmol TE.L^-1) and FRAP (638.4 to 451.4 mmol TE.L^-1) assays. The R100 sample demonstrated the highest iron-chelating ability during biotransformation until 12 h of biotransformation (95.6 % to 52.7 %). The duration of biotransformation significantly influenced the chemical properties and antioxidant capacity of arugula and beetroot extracts. Notably, the 100 % arugula extract produced the highest nitrite concentration at 24 h (245.4 ppm). However, extended incubation time appeared to diminish the antioxidant potential of the extracts. In conclusion, the biotransformation of beetroot, arugula, and their mixtures using commercial starter cultures presents a promising strategy for developing natural bio-additives for the meat industry, provided that phenolic content and antioxidant properties are carefully preserved.

01 Jul 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A novel SERRS approach for the highly sensitive detection of bilirubin levels in urine

Article

Author: Jiang, Wen-Xiang ; Li, Jian-Feng ; Wen, Bao-Ying ; Zhang, Yue-Jiao ; Zhou, Jing-Wen

Bilirubin, as a major component of human bile and a byproduct of red blood cell metabolism, plays an essential role in diagnosing jaundice and assessing liver function. Surface-enhanced resonance Raman spectroscopy (SERRS) is a highly sensitive detection technique that emerged from the synergy of resonance Raman spectroscopy and surface-enhanced Raman spectroscopy (SERS). This technology not only provides molecular fingerprint information but also offers rapid detection, interference resistance, and high selectivity, making it particularly suitable for specific biological system detection. Herein, we have developed an innovative SERRS technique for efficiently measuring bilirubin levels in urine. This method involves precisely adjusting the pH of sodium nitrite to 1, oxidizing bilirubin to biliverdin. Subsequently, a portable Raman spectrometer with an excitation wavelength of 785 nm is used to emit its resonance Raman signal, achieving high-sensitivity and selective rapid detection. Through this approach, we have achieved the quantification of a wide linear dynamic range spanning from 860 nmol/L to 34.2 μmol/L, characterized by an excellent correlation coefficient of 0.99 and a remarkably low detection limit of 860 pmol/L, which is significantly below that of traditional detection methods. Moreover, in the analysis of real samples, minimal pre-treatment is required to achieve high sensitivity and expedited detection. The entire procedure is completed in merely 1 min, with recovery rates falling between 80 % and 100 %. This approach paves the way for the specific and rapid detection of biomarkers using Raman spectroscopy.

01 May 2025·ENERGY

Phase diagram calculation and neural network prediction of nitrate/nitrite molten salts with wide working temperature range for thermal storage system

Author: Wang, Zixuan ; Lu, Yuanwei ; Zhang, Cancan ; Wang, Yuanyuan ; Wu, Yuting

Molten salt with wide temperature range is an excellent thermal energy storage medium, which is essential in concentrating solar power plants.In this work, the novel nitrate/nitrite molten salts for thermal energy storage (TES) were designed.The eutectic points of the NaNO₃-KNO₂ and NaNO₃-NaNO₂ systems were predicted by developing the back-propagation (BP) neural network optimized based on genetic algorithm (GA).In addition, the phase diagrams of the molten salts were calculated using the thermodn. sub-regular solution model (SSM).The nitrate/nitrite thermodn. database was supplemented.Based on exptl. validation, both BP-GA and SSM methods were effective means of predicting the molten salts eutectic points, with maximum prediction errors of 7.9 % and 6.0 %, resp.The liquid usage temperature ranges for NaNO₃-KNO₂ and NaNO₃-KNO₂ eutectic salts were 152.4-612.2 °C and 232.4-602.0 °C, resp.The sensible heat storage d. of NaNO₃-KNO₂ molten salt was 729.8 kJ/kg, which was about 63.5 % higher than the Solar salt.This work not only provided methods for screening target molten salt, but also provided the theor. and exptl. basis for the widespread application of molten salts for TES.In future work, we will further optimize the prediction algorithm and explore the long-term thermal stability of the preferred molten salts.

News (Medical) associated with Sodium nitrite

02 Apr 2025

·pipelinereview.com

AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline

Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new investors Current investors ARCH Venture Partners, Forbion Ventures, ND Capital, and others also participated AIRNA expected to file clinical trial application for Alpha-1 antitrypsin deficiency (AATD) RNA editing product candidate (AIR-001) with potential best-in-class profile in 2H 2025 CAMBRIDGE, MA, USA & TÜBINGEN, Germany I April 01, 2025 I AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the closing of an oversubscribed $155 million Series B financing. The financing was led by Venrock Healthcare Capital Partners, co-led by Forbion Growth, and included participation from RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital, and other new and existing investors. AIRNA will use the proceeds to advance its lead RNA editing product candidate (AIR-001) for AATD into a Phase 1/2 clinical trial, and to develop a pipeline of novel RNA-editing medicines for cardiometabolic and other diseases. “AIRNA is developing a new class of genetic medicines that could provide functional cures for a wide range of diseases,” said Kris Elverum, President and Chief Executive Officer of AIRNA. “This partnership of new and existing investors allows us to rapidly deliver AIR-001 to patients with AATD, as well as progress a pipeline of medicines to realize the full potential of RNA editing.” AATD is caused by mutations in the SERPINA1 gene that lead to insufficient levels of functional alpha-1 antitrypsin (M-AAT) protein, which results in lung and liver disease. AIR-001 precisely repairs the most common, harmful SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver disease and restore functional M-AAT production. AIR-001 was designed for potent and durable M-AAT production, convenient, subcutaneous dosing, and well-tolerated safety to give patients a preferred therapeutic option. “Patients with AATD have limited therapeutic options, and AIRNA is developing a potentially best-in-class medicine that has been optimized for potency, durability, and safety,” said Ken Greenberg, M.D., partner at Venrock Healthcare Capital Partners. “Venrock is thrilled to collaborate with the tremendous team at AIRNA, and a world-class investor syndicate, to bring novel RNA editing medicines to patients.” AIRNA’s proprietary platform harnesses natural mechanisms to potently edit a target RNA with a safe and flexible medicine. Precise RNA editing has unique potential to safely introduce beneficial genetic variants that promote optimal health, in addition to repairing disease-driving mutations, such as those causing AATD. AIRNA identifies variants that drive health through human genetics, and is developing new medicines to transform the lives of patients with cardiometabolic and other diseases. “AIRNA’s innovative approach to RNA editing has the distinctive potential to improve health across large populations by introducing healthy genetic variants for many conditions. We are excited to support the expansion of AIRNA’s pipeline of life-changing medicines and the advancement AIR-001 into the clinic,” said Dirk Kersten, Managing Partner at Forbion. Alongside this financing, AIRNA announced the appointment of Melissa McCracken, Ph.D., a partner at Nextech Invest, to the Board of Directors. Dr. McCracken has a track record of growing the next generation of innovative biopharma companies, with a focus on precision approaches. About AIRNA AIRNA is harnessing advances in genetics to develop transformative RNA-editing medicines that improve human health across both rare and broad populations. RNA editing offers the precision of genetic medicine approaches while maintaining treatment convenience, flexibility, and reversibility. Our proprietary platform is based on groundbreaking research by pioneers of the field and company co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University) and enables optimal potency, safety, and delivery. AIRNA is advancing a robust pipeline of therapeutic candidates that are designed to provide functional cures for severe or chronic diseases by repairing harmful genetic variants or introducing beneficial variants promote optimal health. AIRNA’s lead program has the potential to be a best-in-class therapeutic for alpha-1 antitrypsin deficiency (AATD). AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen, Germany. Learn more at https://airna.com/ . SOURCE: AIRNA

Executive ChangesiRNA

02 Apr 2025

·www.pharmaceutical-technology.com

AIRNA secures $155m to bring RNA-candidate to clinic

AIRNA’s total capital raised so far is $245m. Credit: sesame via Getty Images. AIRNA has raised $155m in Series B financing to advance its RNA editing pipeline, and kick-start a clinical trial for its lead candidate, AIR-001. Venrock Healthcare Capital Partners and Forbion Growth co-led the new round, bringing AIRNA’s total raised capital to $245m. The US and Germany-based biotech plans to file a clinical trial application (CTA) for its lead candidate, AIR-001, for alpha-1 antitrypsin deficiency (AATD) by H2 2025. The company is developing AIR-001 as an investigational RNA editor – a therapy designed to modify RNA sequences to correct disease-causing mutations. This approach is different to DNA editing approaches such as clustered regularly interspaced short palindromic repeats (CRISPR), which make permanent changes to the genome. RNA editing is a reversible process that allows for targeted corrections without altering the underlying genetic code. The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 and the further development of other RNA-editing candidates, primarily targeting cardiometabolic diseases. AATD is a rare genetic disorder caused by mutations in the SERPINA1 gene, which encodes the AAT protein. Under normal circumstances, AAT is produced in the liver and transported to the lungs, where it regulates enzyme activity to prevent tissue damage. In patients with AATD, mutations can prevent AAT from exiting the liver, leading to toxic protein accumulation that damages the liver while also depriving the lungs of necessary protection. This can result in progressive lung disease, liver dysfunction, and symptoms such as shortness of breath, fatigue, and jaundice. The AATD treatment landscape is becoming increasingly competitive as multiple biotechs advance RNA-editing candidates. Korro Bio is investigating its candidate KRRO-110 in the Phase I/IIa REWRITE clinical trial (NCT06677307), with interim data expected in H2 2025. The company announced last month that the dosing of the first two cohorts had been completed, and the trial is expected to conclude next year. Wave Life Sciences is developing WVE-006, which demonstrated targeted RNA editing in the first two patients treated in the Phase Ib/IIa RestorAATion-2 clinical trial (NCT06405633). The growing interest in RNA editing has also drawn investment from major pharmaceutical companies. In November 2023, Roche expanded its partnership to develop a one-time RNA editing therapy using ShapeTX’s AI-powered platform for an undisclosed disease. In September 2024, Novo Nordisk and Korro Bio announced a collaboration leveraging Korro’s OPERA platform to enable oligonucleotide-directed RNA edits for two undisclosed targets, initially focused on cardiometabolic diseases. The deal included up to $530m in upfront, development, and commercial milestone payments, along with tiered royalties and R&D funding. Not all genetic medicine approaches for AATD have progressed as planned. In January 2025, Intellia Therapeutics discontinued the development of its CRISPR-based gene therapy NTLA-3001, which was intended to correct the SERPINA1 mutation at the DNA level. Preparations for the Phase I/II trial were halted, along with other early-stage programmes, signalling a shift in the company’s pipeline priorities. With fresh funding and a CTA planned for later this year, AIRNA is positioning itself within the growing RNA editing field. Forbion managing partner Dirk Kersten said: “AIRNA’s innovative approach to RNA editing has the distinctive potential to improve health across large populations by introducing healthy genetic variants for many conditions. We are excited to support the expansion of AIRNA’s pipeline of life-changing medicines and the advancement of AIR-001 into the clinic.”

Clinical StudyOligonucleotidesiRNAGene Therapy

01 Apr 2025

·www.businesswire.com

AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline

CAMBRIDGE, Mass. & TÜBINGEN, Germany--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the closing of an oversubscribed $155 million Series B financing. The financing was led by Venrock Healthcare Capital Partners, co-led by Forbion Growth, and included participation from RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital, and other new and existing investors. AIRNA will use the proceeds to advance its lead RNA editing product candidate (AIR-001) for AATD into a Phase 1/2 clinical trial, and to develop a pipeline of novel RNA-editing medicines for cardiometabolic and other diseases. “AIRNA is developing a new class of genetic medicines that could provide functional cures for a wide range of diseases,” said Kris Elverum, President and Chief Executive Officer of AIRNA. “This partnership of new and existing investors allows us to rapidly deliver AIR-001 to patients with AATD, as well as progress a pipeline of medicines to realize the full potential of RNA editing.” AATD is caused by mutations in the SERPINA1 gene that lead to insufficient levels of functional alpha-1 antitrypsin (M-AAT) protein, which results in lung and liver disease. AIR-001 precisely repairs the most common, harmful SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver disease and restore functional M-AAT production. AIR-001 was designed for potent and durable M-AAT production, convenient, subcutaneous dosing, and well-tolerated safety to give patients a preferred therapeutic option. “Patients with AATD have limited therapeutic options, and AIRNA is developing a potentially best-in-class medicine that has been optimized for potency, durability, and safety,” said Ken Greenberg, M.D., partner at Venrock Healthcare Capital Partners. “Venrock is thrilled to collaborate with the tremendous team at AIRNA, and a world-class investor syndicate, to bring novel RNA editing medicines to patients.” AIRNA’s proprietary platform harnesses natural mechanisms to potently edit a target RNA with a safe and flexible medicine. Precise RNA editing has unique potential to safely introduce beneficial genetic variants that promote optimal health, in addition to repairing disease-driving mutations, such as those causing AATD. AIRNA identifies variants that drive health through human genetics, and is developing new medicines to transform the lives of patients with cardiometabolic and other diseases. “AIRNA’s innovative approach to RNA editing has the distinctive potential to improve health across large populations by introducing healthy genetic variants for many conditions. We are excited to support the expansion of AIRNA’s pipeline of life-changing medicines and the advancement AIR-001 into the clinic,” said Dirk Kersten, Managing Partner at Forbion. Alongside this financing, AIRNA announced the appointment of Melissa McCracken, Ph.D., a partner at Nextech Invest, to the Board of Directors. Dr. McCracken has a track record of growing the next generation of innovative biopharma companies, with a focus on precision approaches. About AIRNA AIRNA is harnessing advances in genetics to develop transformative RNA-editing medicines that improve human health across both rare and broad populations. RNA editing offers the precision of genetic medicine approaches while maintaining treatment convenience, flexibility, and reversibility. Our proprietary platform is based on groundbreaking research by pioneers of the field and company co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University) and enables optimal potency, safety, and delivery. AIRNA is advancing a robust pipeline of therapeutic candidates that are designed to provide functional cures for severe or chronic diseases by repairing harmful genetic variants or introducing beneficial variants promote optimal health. AIRNA’s lead program has the potential to be a best-in-class therapeutic for alpha-1 antitrypsin deficiency (AATD). AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen, Germany. Learn more at https://airna.com/.

Executive ChangesiRNA

100 Deals associated with Sodium nitrite

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Poisoning	United States	Hope Pharmaceuticals, Inc.	14 Feb 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral Vascular Diseases	Phase 2	United States	ALT5 Sigma Corp.	23 Jul 2020
COVID-19	Phase 2	United States	Hope Pharmaceuticals, Inc.	22 Jul 2020
Lung Injury	Phase 2	United States	Hope Pharmaceuticals, Inc.	22 Jul 2020
Respiratory Distress Syndrome, Acute	Phase 2	United States	Hope Pharmaceuticals, Inc.	22 Jul 2020
Respiratory Failure	Phase 2	United States	Hope Pharmaceuticals, Inc.	22 Jul 2020
Heart failure with normal ejection fraction	Phase 2	United States	Aires Pharmaceuticals, Inc.	10 Aug 2016
Cystic Fibrosis	Phase 2	United States	Mast Therapeutics, Inc.	01 Feb 2016
Pseudomonas Infections	Phase 2	United States	Mast Therapeutics, Inc.	01 Feb 2016
Diabetic peripheral neuropathic pain	Phase 2	United States	TheraVasc, Inc.	28 Apr 2015
Intracranial Aneurysm	Phase 2	United States	Hope Pharmaceuticals, Inc.	01 Jun 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03015402 (PH-HFpEF, CTgov)	Phase 2	Secondary hypertension \| Heart failure with normal ejection fraction \| Hypertension, Pulmonary	33	Placebo Oral Capsule	kxbvwhsjeb(zxkzazpsko) = ipnwvhfnfn blzwaigivc (xdcuchkekl, 11.34) View more	-	07 Jun 2024
NCT02713126 (INABLE, Pubmed \| Mayo Clin Proc) Manual	Phase 2	Heart failure with normal ejection fraction	92	Inorganic Nitrite 40 mg	gfuqaxrfvm(fbttcnyfgq) = rmfpbuqjud xosoypqltr (ivpxoquonf, 0.3 - 1.2) View more	Negative	01 Feb 2024
NCT02713126 (INABLE \| INABLE-Training Trial \| RELAX, NCT00763867; Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction, NCT02053493; Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF, NCT02742129; Inorganic Nitrite to Enhance Benefits From Exercise Training in Heart Failure With Preserved Ejection Fraction [HFpEF], NCT02713126, CTgov)	Phase 2	Heart failure with normal ejection fraction	92	Cardiac Exercise Training (Placebo)	abtvpxhasx(csyeultdgp) = riwfdgnpeu ksvyxwkugp (rrxbsctuaf, 2.10) View more	-	26 Apr 2023
				Cardiac Exercise Training+Sodium Nitrite (Sodium Nitrite)	abtvpxhasx(csyeultdgp) = pojaxatfpm ksvyxwkugp (rrxbsctuaf, 1.51) View more
NCT02433977 (NICLA, CTgov)	Phase 2	Asthma	6	Sodium Nitrate+Sodium Nitrite	owvbmsqdkh(dyblxszbzu) = kuoirctyjl aaseuqgdpy (jcxqjwpavn, 10.4) View more	-	26 Mar 2021
NCT02262078 \| NCT01932606 (Pubmed \| Eur J Heart Fail)	Phase 2	Heart failure with normal ejection fraction	51	Inhaled sodium nitrite	fcwenkbhga(qzcpozpsgs) = yvwdtqgjnx qugtelehas (htrrfbrwzd ) View more	-	09 Jan 2021
				Intravenous sodium nitrite	fcwenkbhga(qzcpozpsgs) = wkkattzicl qugtelehas (htrrfbrwzd ) View more
NCT02412852 (CTgov)	Phase 2	Diabetic peripheral neuropathic pain	26	Sodium nitrite (40 mg TV1001sr)	bmwfttbsxk = etofdpkyxi jkknasrkwv (yfjerwtecl, rfbpsbksyc - ixjhnwrngg) View more	-	24 Apr 2020
				Sodium nitrite (80 mg TV1001sr)	bmwfttbsxk = jqgaencgwk jkknasrkwv (yfjerwtecl, wqtflcrdel - aaqsesrjgo) View more
NCT02918552 (ONOH, CTgov)	Phase 2	Heart failure with normal ejection fraction	15	sodium nitrite (Sodium Nitrite)	skctucnysw(nwhucenyyd) = dcomaxukro yjxnydkbzy (bbnfvkkctc, 1.5) View more	-	22 Jan 2020
				placebo (Placebo)	skctucnysw(nwhucenyyd) = ubsyekrtvd yjxnydkbzy (bbnfvkkctc, 0.5) View more
NCT01681810 (ONTX, CTgov)	Phase 2	Metabolic Syndrome \| Hypertension	20	14Nitrogen Sodium Nitrite	hrfmdlksma(rdggcmqcne) = nxsonhtalv njxsbrbhqn (dwxjmjcqsr, 0.58) View more	-	16 Apr 2019
NCT02742129 (INDIE-HFpEF, CTgov)	Phase 2	Heart failure with normal ejection fraction	105	Placebo (AIR001 Crossover to Placebo)	smlotgeryb(oygwltvjsq) = dklgqcuocy ldqnqxeqxh (siwiyugmsz, 3.2) View more	-	13 Mar 2019
				Placebo (Placebo Crossover to AIR001)	smlotgeryb(oygwltvjsq) = kapolmomki ldqnqxeqxh (siwiyugmsz, 3.8) View more
NCT02742129 (Pubmed \| JAMA)	Phase 2	Heart failure with normal ejection fraction	105	Inorganic Nitrite	fpsycmcrsz(swypudsdap) = ybwzgbhzqi fuuloigwnm (uvdjhuxxfh ) View more	-	06 Nov 2018
				Placebo	fpsycmcrsz(swypudsdap) = ukbdvtdfnt fuuloigwnm (uvdjhuxxfh ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sodium nitrite

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation